News

Nativis Research Partner to Present at COGNO Conference in Australia

Nativis Research Partner to Present at COGNO Conference in Australia

SEATTLE – October 17, 2017 –  Nativis, Inc., a clinical stage life science, bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced encouraging data supporting the use of ultra-low radio frequency energy (ulRFE®) in patients with recurrent glioblastoma (GBM). Dr. Anthony J. Dowling, a Nativis research partner at St. Vincent’s Hospital, Melbourne, Australia, will present the data derived in the first-in-human study in Australia using the Nativis Voyager system at the 10th COGNO Annual Scientific Meeting, Monday 23rd – Tuesday 24th October 2017 at the Rydges Melbourne Hotel, Melbourne, Australia.

The Nativis Voyager system, a non-invasive investigational device, was studied at St. Vincent’s Hospital Melbourne in a first-in-human feasibility study on 15 patients to assess safety and feasibility of the treatment for rGBM. Dowling’s presentation concludes that the Nativis Voyager system appears to be safe for the treatment of rGBM, as no serious device-related adverse events were reported.  Additionally, the presentation concludes that the Nativis Voyager system appears to have clinical utility for the treatment of rGBM, as up to 20% of patients were progression free for at least 6 months.

“I am excited to present the results from our clinical program with Nativis at this year’s COGNO Annual Scientific Meeting,” said Dowling. “The Nativis Voyager technology is unique in its approach in the treatment of patients with rGBM. It is a simple device that is easy and comfortable for the patient to wear. We are planning further clinical trials with Nativis to produce additional data.”

“Our initial data from this and other studies demonstrate that specific ulRFE can be used to knock down specific key pathways associated with cancer signaling,” stated Chris E. Rivera, Nativis’ Chief Executive Officer. “Our novel technology has the potential to transform the way we treat cancer. With these encouraging data in hand, we will continue to develop the Nativis Voyager system for the treatment of GBM with the aim to expand to additional indications in the future.”  Nativis has two additional GBM studies ongoing– one for newly diagnosed GBM in the US and the other for rGBM in the US and in Australia (www.clinicaltrials.gov).

Earlier this year, Nativis announced an exclusive license agreement with Teijin Limited of Japan for the development and commercialization of Nativis’ proprietary technology for the potential treatment of GBM in the Japanese market. Teijin Limited is a comprehensive Japanese company expanding businesses in high-performance materials, pharmaceuticals, home healthcare, product converting and information technology.

About Nativis, Inc.

Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE®) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive investigational device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.  Nativis Voyager® ulRFE® system for GBM is an investigational medical device, limited by United States law to investigational use only.

Media Relations Contact:

Aaron Blank / Amber Benson

ablank@feareygroup.com / abenson@feareygroup.com

206-343-1543

Back to News